Literature DB >> 11104570

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group.

G Palmieri1, A Cossu, P A Ascierto, G Botti, M Strazzullo, A Lissia, M Colombino, M Casula, C Floris, F Tanda, M Pirastu, G Castello.   

Abstract

Malignant melanoma (MM) is thought to arise by sequential accumulation of genetic alterations in normal melanocytes. Previous cytogenetic and molecular studies indicated the 9p21 as the chromosomal region involved in MM pathogenesis. In addition to the CDKN genes (p16/CDKN2A, p15/CDKN2B and p19(ARF), frequently inactivated in familial MM), widely reported data suggested the presence within this region of other melanoma susceptibility gene(s). To clearly assess the role of the 9p21 region in sporadic melanoma, we evaluated the presence of microsatellite instability (MSI) and loss of heterozygosity (LOH) in primary tumours as well as in synchronous or asynchronous metastases obtained from the same MM patients, using 9 polymorphic markers from a 17-cM region at 9p21. LOH and MSI were found in 27 (41%) and 11 (17%), respectively, out of 66 primary tumours analysed. In corresponding 58 metastases, MSI was found at higher rate (22; 38%), whereas a quite identical pattern of allelic deletions with 27 (47%) LOH+ cases were observed. Although the CDKN locus was mostly affected by LOH, an additional region of common allelic deletion corresponding to marker D9S171 was also identified. No significant statistical correlation between any 9p21 genetic alteration (LOH, MSI or both) and clinicopathological parameters was observed. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104570      PMCID: PMC2363459          DOI: 10.1054/bjoc.2000.1513

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.

Authors:  L Liu; A M Goldstein; M A Tucker; H Brill; N A Gruis; D Hogg; N J Lassam
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

3.  Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma.

Authors:  S Birindelli; G Tragni; C Bartoli; G N Ranzani; F Rilke; M A Pierotti; S Pilotti
Journal:  Int J Cancer       Date:  2000-04-15       Impact factor: 7.396

4.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

5.  A cell cycle regulator potentially involved in genesis of many tumor types.

Authors:  A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

6.  Homozygous deletions within human chromosome band 9p21 in melanoma.

Authors:  J W Fountain; M Karayiorgou; M S Ernstoff; J M Kirkwood; D R Vlock; L Titus-Ernstoff; B Bouchard; S Vijayasaradhi; A N Houghton; J Lahti
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

Authors:  A Kamb; D Shattuck-Eidens; R Eeles; Q Liu; N A Gruis; W Ding; C Hussey; T Tran; Y Miki; J Weaver-Feldhaus
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

8.  Loss of heterozygosity in sporadic primary cutaneous melanoma.

Authors:  E Healy; I Rehman; B Angus; J L Rees
Journal:  Genes Chromosomes Cancer       Date:  1995-02       Impact factor: 5.006

9.  Identification of a founder BRCA2 mutation in Sardinia.

Authors:  M Pisano; A Cossu; I Persico; G Palmieri; A Angius; G Casu; G Palomba; M G Sarobba; P C Rocca; M F Dedola; N Olmeo; A Pasca; M Budroni; V Marras; A Pisano; A Farris; G Massarelli; M Pirastu; F Tanda
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

10.  Two target regions of allelic loss on chromosome 9 in urinary-bladder cancer.

Authors:  K Ohgaki; K Minobe; K Kurose; A Iida; T Habuchi; O Ogawa; Y Kubota; M Akimoto; M Emi
Journal:  Jpn J Cancer Res       Date:  1999-09
View more
  9 in total

1.  Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma.

Authors:  Denitsa Koynova; Ekaterina Jordanova; Nicole Kukutsch; Pieter van der Velden; Draga Toncheva; Nelleke Gruis
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-15       Impact factor: 4.553

2.  Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation.

Authors:  M R Hussein; A K Haemel; O Sudilovsky; G S Wood
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

3.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

4.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

Authors:  Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

5.  LOH analysis of free DNA in the plasma of patients with mucosal malignant melanoma in the head and neck.

Authors:  Ryo Takagi; Daisuke Nakamoto; Jun-etsu Mizoe; Hirohiko Tsujii
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

6.  A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.

Authors:  Tianhong Li; Scott D Christensen; Paul H Frankel; Kim A Margolin; Sanjiv S Agarwala; Thehang Luu; Philip C Mack; Primo N Lara; David R Gandara
Journal:  Invest New Drugs       Date:  2010-10-22       Impact factor: 3.850

Review 7.  Deficient mismatch repair: Read all about it (Review).

Authors:  Susan Richman
Journal:  Int J Oncol       Date:  2015-08-12       Impact factor: 5.650

8.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.

Authors:  Mario Falchi; Veronique Bataille; Nicholas K Hayward; David L Duffy; Julia A Newton Bishop; Tomi Pastinen; Alessandra Cervino; Zhen Z Zhao; Panos Deloukas; Nicole Soranzo; David E Elder; Jennifer H Barrett; Nicholas G Martin; D Timothy Bishop; Grant W Montgomery; Timothy D Spector
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

Review 9.  Issues affecting molecular staging in the management of patients with melanoma.

Authors:  G Palmieri; M Casula; M C Sini; P A Ascierto; A Cossu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.